Physician profile
Patrick C Howell
NPI 1174293518
$4,796.48
in general payments reported to CMS, 2019-2025
34 companies · $2,234 in 2025
The $2,234 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $132 · 2023: $348 · 2024: $2,083 · 2025: $2,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,664.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $932.82 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $492.13 | 2023-2025 | Wegovy |
| Astellas Pharma US INC | $366.33 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $347.34 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $332.05 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $320.80 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $204.94 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.98 | 2024-2025 | Xifaxan |
| Pfizer INC. | $170.55 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.11 | 2022-2025 | Jardiance |
| Lundbeck LLC | $137.64 | 2024-2025 | Rexulti |
| Abbvie INC. | $123.38 | 2023-2024 | |
| Glaxosmithkline, LLC. | $95.79 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $95.22 | 2023-2025 | Nexletol |
| Corcept Therapeutics | $85.80 | 2024-2025 | Korlym |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $84.79 | 2022-2025 | Xarelto, Spravato |
| Dexcom, INC. | $83.11 | 2024-2025 | Dexcom G6 Transmitter |
| Tolmar, INC. | $79.76 | 2024-2025 | Jatenzo |
| Novartis Pharmaceuticals Corporation | $75.32 | 2022-2024 | |
| Corium, LLC | $60.25 | 2023-2024 | Azstarys |
| Shield Therapeutics INC | $53.97 | 2025 | |
| Idorsia Pharmaceuticals US INC | $48.49 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $36.91 | 2023-2024 | Auvelity |
| Tris Pharma INC | $34.35 | 2024 | Dyanavel Xr |
| Amgen INC. | $31.57 | 2023-2024 | Otezla, Repatha |
| Alexion Pharmaceuticals, INC. | $27.80 | 2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $27.44 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Gilead Sciences, INC. | $23.86 | 2024 | |
| Boston Scientific Corporation | $23.16 | 2025 | General - Pain Management |
| Phathom Pharmaceuticals, INC. | $20.40 | 2023 | Voquezna |
| Depuy Synthes Sales INC. | $20.18 | 2025 | Orthovisc |
| Seqirus USA INC | $15.84 | 2025 | Fluad, Flucelvax |
| Amarin Pharma, INC. | $14.62 | 2022 | |
| Theracosbio, LLC | $9.78 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.